Venbio Partners LLC

About

venBio Skip to content Investor login Venture capital for Life Sciences We are a life sciences investment firm partnering with industry leaders to build game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs. Founded in 2011, venBio’s venture funds comprise nearly in committed capital $ 1.1 billion approved drugs 1 FDA diseases FOR 1 Companies that Matter We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes intellectual property (IP), chemistry, manufacturing (CMC), and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with. Our mission We seek out teams who are developing treatments that will have a meaningful impact on patient care. Our mission is to put our companies in the best possible position to succeed, by helping teams think through the best development plan to bring these therapies to patients. Learn more about us Latest news Sep 19, 2025 Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree Read more Jul 22, 2025 Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion Read more Jul 10, 2025 Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivot

Key Contact